Co-processing: A Multifaceted Approach for Enhancing Density & Powder Flow

San Kiang is the Chief Technology Officer Drug Product at J-Star Research/Porton. He deploys particle engineering and co-processing techniques to resolve API and formulation issues especially those related to powder flow and dosage form dissolution rates. As a Research Professor at Rutgers University, he worked on research projects in the Engineering Research Center for Structured Organic Particles and the Chemical Engineering Department. Research focus is on continuous manufacturing (CM) and particle engineering, more specifically how the material properties of API can be engineered and how these properties affect CM equipment train and drug product performance.

San Kiang has 35 years of pharmaceutical development and technology transfer experience in Bristol-Myers Squibb covering both Active Pharmaceutical Ingredient (API) and Drug Product (DP) areas. PhD chemical engineer with experience in directing multi-disciplinary teams in pharmaceutical, chemical, and biochemical development and manufacture. He directed and/or participated in 12 NDA projects that were eventually commercialized and successfully participated in one of the first NDA filings using QBD paradigm. In this filing, he led the use of risk assessment and process modeling with emphasis on fundamental mechanistic understanding for drug development. Well recognized expert in crystallization, particle engineering, reaction engineering, continuous processing (both DP and API), as well as the design of pharmaceutical composite materials through co-processing.

Kaushalendra leads advancements in particle engineering and drug product risk assessment. He skillfully employs techniques like particle engineering, crystal engineering, and coprocessing to optimize the behavior and effectiveness of active pharmaceutical ingredients (API) and their respective formulations, placing an emphasis on enhancing powder flow, density, solubility, and dissolution rates.